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Objective: The aim of this study is to assess the association between the degree of insulin resistance and the
different components of the metabolic syndrome among Chinese children and adolescents. Moreover, to
determine the cut-off values for homeostasis model assessment of insulin resistance (HOMA-IR) at MS risk.
Methods: 3203 Chinese children aged 6 to 18 years were recruited. Anthropometric and biochemical parameters
were measured. Metabolic syndrome (MS) was identified by a modified Adult Treatment Panel III (ATP III) definition.
HOMA-IR index was calculated and the normal reference ranges were defined from the healthy participants.
Receiver operating characteristic (ROC) analysis was used to find the optimal cutoff of HOMA-IR for diagnosis of MS.
Results: With the increase of insulin resistance (quintile of HOMA-IR value), the ORs of suffering MS or its related
components were significantly increased. Participants in the highest quintile of HOMA-IR were about 60 times more
likely to be classified with metabolic syndrome than those in the lowest quintile group. Similarly, the mean values
of insulin and HOMA-IR increased with the number of MS components. The present HOMA-IR cutoff point
corresponding to the 95th percentile of our healthy reference children was 3.0 for whole participants, 2.6 for
children in prepubertal stage and 3.2 in pubertal period, respectively. The optimal point for diagnosis of MS was 2.3
in total participants, 1.7 in prepubertal children and 2.6 in pubertal adolescents, respectively, by ROC curve, which
yielded high sensitivity and moderate specificity for a screening test. According to HOMA-IR > 3.0, the prevalence
of insulin resistance in obese or MS children were 44.3% and 61.6% respectively.
Conclusions: Our data indicates insulin resistance is common among Chinese obese children and adolescents, and
is strongly related to MS risk, therefore requiring consideration early in life. As a reliable measure of insulin
resistance and assessment of MS risk, the optimal HOMA-IR cut-off points in this cohort were developed with
variation regarding puberty. HOMA-IR may be useful for early evaluating insulin resistance in children and teenagers
and could have a long-term benefit of preventive and diagnostic therapeutic intervention.
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Childhood obesity has experienced an important in-
crease all over the world. It has been associated with
the rising prevalence of many metabolic complica-
tions, such as hyperlipidemia, hyperglycemia and high
blood pressure [1]. Many of them are already present
during childhood and tend to persist into adulthood
or further develop into metabolic syndrome (MS),
and therefore increase the risk for development of
cardiovascular disease (CVD) [2].
Insulin resistance is the primary metabolic disorder
associated with obesity and appears to be the pri-
mary mediator of MS [3]. Identification of children
with insulin resistance has been proposed as a strat-
egy for identifying high-risk children for targeting
MS interventions. The gold-standard technique for
assessment of insulin sensitivity is the hyperinsulin-
emiceuglycemic clamp [4]; and another accepted method
is the minimal-model analysis frequently sampled
intravenous glucose tolerance test (FSIVGTT) [5].
These tests are invasive, labor intensive, and expensive,
which can be used for research purposes only. As a
more convenient method to measure insulin resist-
ance, the homeostasis model assessment of insulin re-
sistance (HOMA-IR) was therefore developed and
widely used in clinical and epidemiologic studies [6,7].
In children and adolescents, HOMA-IR has been
validated as a surrogate measure of insulin resistance
in several studies, showing high correlations with
clamp or FSIVGTT measures [8,9]. However, it is
more difficult to define HOMA-IR cut-off points for
diagnosis of insulin resistance in youths than in
adults, because there is lack of longitudinal evidence
in youths for risk prediction of cardiovascular out-
comes. Alternatively, in most studies, cut-off points
for diagnosis of insulin resistance have been defined
based on HOMA-IR distribution in reference popula-
tion, but due to the influence factors such as puberty
development and ethnic difference, values varied obvi-
ously from 1.8, 2.5, 3.2, to >4 according to the differ-
ent reference population [10-12]. On the other hand,
presence of pediatric MS, as a risk for future CVD,
has been considered alternatively for defining cut-off
values of HOMA-IR [9], but population-based studies
are limited and there even exists debates on how and
to what extent IR is associated with MS and its
components.
In this context, our study aims are to evaluate the
association of IR with each of the components of MS
and to determine HOMA-IR cut-off values of different
pubertal status regarding the diagnosis of MS based
on a large cohort of Chinese schoolchildren. To our
knowledge, there is lack of this kind of study in
population- based samples of Chinese children.Methods
Subjects
The data obtained from a cross-sectional population
based survey conducted in Beijing area (the BCAMS
cohort study) were analyzed [13,14]. The BCAMS study
evaluated the prevalence of obesity and related meta-
bolic abnormalities (hypertension, hyperglycemia and
dyslipidemia) from a representative sample of Beijing
school-age children (n = 19593, ages 6–18 years, 50%
boys) between April and October 2004. Within this large
group, 4500 of them were identified as having one of the
following disorders: overweight defined by body mass
index (BMI), increased cholesterol (≥5.2 mmol/L), trigly-
ceride (TG) ≥ 1.7 mmol/L or fasting glucose ≥5.6 mmol/L
based on finger capillary blood tests. All of the high risk
participants were recruited for the second time of medical
examination. A parallel reference population of 1045
school-age children was also studied. A total of 3203
schoolchildren (1679 boys) who had completed the further
examination without missing data on variables needed for
defining the MS were included in the current study; among
them 420 subjects were diagnosed with MS according to
the modified criteria of Adult Treatment Panel III (ATP III)
definition [13,15] and 1037 subjects with normal weight
status and without any components of MS were included
serving as reference population. Signed informed consent
was obtained from participants and/or parents/guardians.
The BCAMS study was approved by the Ethics Committee
at the Capital Institute of Pediatrics in Beijing.
Clinical and anthropometric measurements
Subjects’ height and weight were measured according
to our standard protocol [16]. BMI was calculated as
weight (kg) divided by height squared (m2). BMI was
converted to age- and sex-standardized percentiles
based on the Centers for Disease Control and Pre-
vention 2000 growth charts, which are not race spe-
cific [17]. Subjects were classified as normal weight
if BMI was 5th ~ 85th percentile, overweight if BMI
was 85th and 95th percentile, or obese if BMI was
above 95th percentile. Waist circumference (WC)
was measured midway between the lowest rib and
the top of the iliac crest. Measurements of right arm
systolic and diastolic blood pressure (SBP and DBP)
were performed 3 times 10 minutes apart and the
mean values of the latter two measurements were
recorded. Pubertal development was assessed by
Tanner stage of breast development in girls and tes-
ticular volume in boys. A testicular volume equal to
or greater than 4 ml in boys and onset of breast de-
velopment in girls were accepted as the criteria for
onset of puberty [18]. This assessment was per-
formed visually by two pediatricians of the same
gender as the child.
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Venous blood samples were collected after an overnight
(≥12 h) fast. The concentrations of plasma glucose (glucose
oxidize method), triglycerides (TG), total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C) and low-
density lipoprotein cholesterol (LDL-C) were assayed using
the Hitachi 7060 C automatic biochemistry analysis system.
HDL-C and LDL-C were measured directly. Insulin
was measured by monoclonal antibody based sandwich
enzyme-linked immuno sorbent assay (ELISA) [19], devel-
oped in the Key Laboratory of Endocrinology, Peking
Union Medical College Hospital, which had an inter-assay
coefficients of variation (CV) of <9.0% and no cross-
reactivity to proinsulin (<0.05%). Fat percentage (FAT%)
was assessed by bioelectrical impedance analysis (BIA,
TANITATBF-300A).
Definition of MS and its related components and
calculation of HOMA-IR
The International Diabetes Federation (IDF) released the
first definition of MS in children and adolescents in
2007. However, it positions central obesity as an essential
element, this almost rules out the possibility of diagnos-
ing MS in a normal weight individual. Therefore, a modi-
fied ATPIII definition was employed in our study, in
which MS was defined by the presence of three or more
of the following five components [13,15]: (1) central
obesity defined as WC ≥ 90th percentile for age and gen-
der (established based on the BCAM study); (2) elevated
systolic and/or diastolic blood pressure ≥ 95th percentile
for age, sex and height (according to the BCAMS study);
(3) hypertriglyceridemia defined as TG ≥1.24 mmol/L,
equal to the 90th percentile of the reference population; (4)
low serum HDL-C (Low-HDL) defined as ≤1.03 mmol/L
i.e., ≤ 5th percentile of the reference population and (5) im-
paired fasting glucose (IFG) defined as ≥ 5.6 mmol/L.
Insulin resistance index was calculated by homeostasis
model assessment of insulin resistance (HOMA-IR) as
(fasting insulin mU/L) × (fasting glucose mmol/L) / 22.5.
Statistical analysis
All statistical analyses were carried out using the
Statistical Package for Social Sciences (SPSS version 15.0
for Windows, Chicago, IL, USA). All skewed distribu-
tions were log transformed for analysis. Results are
expressed as mean ± standard deviation (SD). The mean
values of variables studied by analysis of variance
(ANOVA). Level of significance was accepted as P < 0.05.
Logistic regression generalized estimating equation
models were used to predict the risk of metabolic syn-
drome and its components by quintile of HOMA-IR
after adjustment for age, sex and pubertal stage.
Insulin resistance was defined based on a number of dif-
ferent thresholds, including HOMA-IR threshold above95th percentile for healthy reference population and ROC
analysis to find the cutoff of HOMA-IR among subjects
with and without metabolic syndrome. ROC analysis is a
formal method of assessment for considering trade-offs
between sensitivity and specificity at various test cutoffs or
thresholds. A test with perfect discrimination has a ROC
plot that passes through the upper left corner (100% sensi-
tivity and 100% specificity). The ROC plot for HOMA is
closer to the upper left corner, indicating greater overall
accuracy of the test. To determine the optimal thresholds,
the point on the ROC curve with maximum Youden index
[sensitivity-(1-specificity)], and the point with shortest
distance value form the point (0, 1) [(1 - sensitivity)2 +
(1 - specificity)2] were calculated [20]. These are the two
most commonly used methods for establishing the optimal
cut-off [21].
In order to provide more information for science
research and clinic reference, HOMA-IR cut-offs of
different pubertal stage from the 95th percentile for
healthy reference population along with their corre-
sponding sensitivity and specificity in ROC curves were
also evaluated. The prevalence of insulin resistance
stratified by weight status or metabolic syndrome com-




Anthropometric and metabolic parameters of the study
population by number of MS components are presented
in Table 1. This study included 3203 children and adoles-
cents (1679 boys and 1524 girls) aged 6–18 years. The
mean age’s ± SD of study population were 12.1 ± 3.0 years.
More boys were metabolic disorder than girls(P < 0.05).
As number of MS related components increased, mean
fasting insulin and HOMA-IR, as well as BMI, WC,
FAT%, SBP, DBP and TG were gradually significantly
increased, while HDL-C was significantly decreased.
Risk of suffering from metabolic disorders according to
HOMA-IR quintiles values
Logistic regression models predicting the presence of
the MS and its related components (metabolic disorders)
by quintiles of HOMA-IR values after adjustments for
sex, age, and pubertal stage are shown in Table 2. Using
the group with HOMA-IR values below the 20th
percentile as a reference, it is apparent that the “odds
ratio (OR)” of developing MS or its related metabolic
disorders increased according to a rise of insulin resist-
ance. Participants in the highest HOMA-IR quintile
group were about 60 times more likely to have MS than
those in the lowest quintile group (P<0.001). The OR of
WC, TG and fasting blood glucose increased rapidly
with increasing HOMA-IR level.
Table 1 Characteristics of the study population according to number of metabolic abnormalities
Number of metabolic abnormalities 0 1 2 ≥3
N(M/F) 1340(663/677) 1106(630/476) 640(378/262) 420(229/191)
Age(ys) 11.71 ± 3.09a 11.96 ± 3.09b 11.80 ± 3.04a 12.30 ± 2.95b
Tanner stage 2.58 ± 1.37a 2.75 ± 1.44b 2.71 ± 1.49b 2.84 ± 1.44c
BMI (kg/m2) 18.72 ± 3.36a 21.72 ± 4.17b 25.11 ± 4.03c 27.66 ± 4.11d
WC (cm) 64.15 ± 8.74a 71.62 ± 11.18b 80.96 ± 10.92c 87.48 ± 10.97d
FAT% 19.28 ± 6.60a 24.64 ± 7.78b 29.64 ± 7.35c 31.79 ± 6.94d
SBP (mm Hg) 99.11 ± 10.73a 108.26 ± 11.98b 115.79 ± 12.47c 120.60 ± 11.54d
DBP (mm Hg) 62.13 ± 8.05a 68.46 ± 8.92b 72.77 ± 9.52c 76.25 ± 8.50d
TC (mmol/L) 4.06 ± 0.76a 4.09 ± 0.83a 4.09 ± 0.92a 4.21 ± 0.83b
TG (mmol/L)# 0.78 ± 0.21a 1.03 ± 0.51b 1.19 ± 0.56c 1.67 ± 0.80d
HDL-C (mmol/L) 1.55 ± 0.29a 1.41 ± 0.30b 1.28 ± 0.26c 1.10 ± 0.22d
LDL-C (mmol/L) 2.44 ± 0.70a 2.55 ± 0.75a 2.61 ± 0.84b 2.77 ± 0.73c
FBG (mmol/L) 4.91 ± 0.37a 5.13 ± 0.48b 5.18 ± 0.70b 6.41 ± 0.90c
Fasting Insulin (mU/L)# 6.47 ± 4.25a 10.11 ± 7.33b 13.20 ± 7.84c 20.04 ± 19.35d
HOMA-IR# 1.42 ± 0.96a 2.33 ± 1.77b 3.03 ± 1.81c 4.96 ± 5.48d
Abbreviations: BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, TG triglycerides, HDL-C
high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FBG Fasting blood glucose, HOMA-IR homeostatic model assessment of insulin
resistance. Data are expressed as mean ± SD. #Skewed distributions were logarithmically transformed for one-way ANOVA. Values in the same row with different
superscript letters are significantly different, with P < 0.05, that is, difference groups with the same superscript letter in the same row are no statistical significant.
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reference population
The mean, standard deviation and HOMA-IR threshold
above 95th percentile for a healthy reference population
according to gender, age and pubertal status are given in
Table 3. HOMA-IR threshold above 95th percentile for
the total of healthy reference population (normal-meta-
bolic subjects) is 3.0. We find no significant gender
difference in HOMA-IR threshold above 95th percentile.
In prepubertal stage, HOMA-IR cut-off value from 95th
percentile is 2.6 and so are 3.2 in the pubertal period.
Insulin sensitivity reduces in Tanner stage V and almost
completely recovered by pubertal completion. The simi-
lar result is found in different age ranges. When age is
below 10, most of children are in prepubertal stage, the
HOMA-IR cut-off value from 95th percentile is 2.1.
However, the HOMA-IR threshold above 95th percentile
is rapidly increased to 3.2 when age is up 10 years and
most children go into puberty.
The cutoff of HOMA-IR determined by ROC analysis
among subjects with and without metabolic syndrome
In the total participants pool, the cut-off 2.3 was the best
threshold for MS diagnosis by the modified ATP III
definition. It maximized the Youden index and minimized
the distance on the ROC curve (sensitivity = 80%, specifi-
city = 66%, Youden index = 0.514, distance = 0.194). The
area under the curves in the ROC analysis was 0.806.
When considering puberty development, the cut-off 1.7 is
the best threshold in the prepubertal period, (sensitivity =86%, specificity = 67%, Youden index = 0.529, distance =
0.204). Furthermore, the pubertal period threshold is 2.6
(sensitivity = 78%, specificity = 67%, Youden index =
0.458, distance = 0.153).Areas under the curves in the
ROC analysis are 0.825 in prepubertal and 0.801 in puber-
tal period, respectively (Figure 1).
According to the cut-off points corresponding to the
95th percentile of HOMA-IR for normal subjects (3.0
for all, 2.6 for prepuberty and 3.2 for puberty, respect-
ively), the sensitivity of those points for diagnosis of MS
in ROC analysis are decreased 57%, 54% and 64%,
respectively, while the specificity are increased to 83%,
85% and 80%, respectively.
The prevalence of insulin resistance evaluated by
different cutoffs of HOMA-IR
The prevalence of insulin resistance among those with
ATPIII-defined MS and its related components accord-
ing to our cutoffs using two different definitions in
different pubertal period are given in Table 4. We find
that, regardless of the definition used or the puberty sta-
tus, the prevalence of insulin resistance was substantially
higher in children with MS and its related components.
For prepubertal children, using a threshold of insulin
resistance of HOMA-IR > 1.7, the prevalence of insulin
resistance in children with obesity or MS were 67.2%
and 86.0% respectively; While using the threshold of
HOMA-IR >2.6, the prevalence of insulin resistance
were 39.0% and 53.3%, respectively. Similarly, for puber-
tal adolescents with obesity or MS, when HOMA-IR >
Table 2 Odds ratios of suffering cardiometabolic risk factors according to HOMA-IR quintile in Chinese schoolchildren
Cardiometabolic risk factors HOMA-IR quintile (values)
Quintile1 (<0.94) Quintile2 (0.95-1.59) Quintile3 (1.60-2.31) Quintile4 (2.32-3.44) Quintile5 (>3.45)
MS(ATP III)
OR Referent 3.53 10.69 21.92 57.06
95%CI - 1.41-8.87 4.55-25.10 9.48-50.72 24.87-130.92
P - 0.007 <0.001 <0.001 <0.001
WC≥ 90th percentile
OR Referent 2.50 5.33 11.22 27.96
95%CI - 1.81-3.47 3.90-7.30 8.20-15.37 20.20-38.69
P - <0.001 <0.001 <0.001 <0.001
HDL-C≤ 5th percentile
OR Referent 1.33 1.91 2.88 4.01
95%CI - 0.81-2.19 1.19-3.08 1.82-4.54 2.57-6.25
P - 0.265 <0.001 <0.001 <0.001
TG≥ 90th percentile
OR Referent 2.13 3.71 5.11 9.49
95%CI - 1.50-3.03 2.65-5.19 3.66-7.15 6.82-13.22
P - <0.001 <0.001 <0.001 <0.001
FBG≥ 5.6 mmol/L
OR Referent 1.78 3.65 4.69 9.83
95%CI - 1.03-3.10 2.20-6.06 2.84-7.75 6.05-15.96
P - 0.040 <0.001 <0.001 <0.001
BloodPressure≥ 95th percentile
OR Referent 1.67 2.84 3.52 5.98
95%CI - 1.15-2.42 2.00-4.03 2.48-4.98 4.25-8.41
P - 0.007 <0.001 <0.001 <0.001
Values obtained through logistic regression, adjusted for gender, age and tanner stage.
Yin et al. Diabetology & Metabolic Syndrome 2013, 5:71 Page 5 of 9
http://www.dmsjournal.com/content/5/1/712.6, the prevalence of insulin resistance were 67.9% and
77.3%, and with a HOMA-IR > 3.4, the values were
46.3% and 59.2%, respectively.
Figure 2 shows the prevalence of insulin resistance
stratified by weight status based on different thresholds
for defining insulin resistance. HOMA-IR 1.7, 2.6 or 2.3
were based on receiver-operator curve analysis with or
without considering pubertal status. HOMA-IR 2.6, 3.2
or 3.0 were defined by above the 95th percentiles in
normal-metabolic children and adolescents with or with-
out considering puberty. Regardless of the definition
used, the prevalence of insulin resistance was substan-
tially higher in obese children compared with normal
weight children. According to HOMA-IR 3.0 (95th
percentile of our healthy reference), the prevalence of
insulin resistance in obese adolescents was 44.3%.
Discussion
The prevalence of obesity among children and adolescents
is progressively increasing around the world. One of the
important consequences of obesity is the development ofinsulin resistance (IR). Insulin resistance is a state in
which normal concentrations of insulin produce a subnor-
mal biologic response. This condition has a multifactorial
pathogenesis and is associated with hyperlipidemia,
hyperglycemia, high blood pressure and ovarian hyperan-
drogenism. Those are early state of adult diseases such as
type 2 diabetes mellitus, hypertension, polycystic-ovary
syndrome, cardiovascular disease and MS [22-24].
Although metabolic syndrome has been referred to as the
insulin resistance syndrome, the ATPIII criteria do not
include either fasting insulin level or the homeostasis
model of insulin resistance (HOMA-IR) [15]. There has
been debate about the extent to which the metabolic
syndrome defines the risk of CVD associated with insulin
resistance beyond the risk associated with classic CVD
risk factors (obesity, HDL, triglycerides, and blood pres-
sure) [25]. Therefore, it would be useful to understand the
extent to which the presence of the syndrome is associ-
ated with insulin resistance.
In line with previous population-based studies [26,27],
we found that insulin resistance and MS were significantly
Table 3 The 95th percentiles of HOMA-IR according to
gender, age and tanner stage in normal weight children
without related components of MS
N Mean Std. deviation 95th
Total 1037 1.29 1.11 3.0
Sex
Male 442 1.21 0.93 3.1
Female 595 1.34 0.83 2.9
Age(years)
6-9 278 0.81 0.57 2.1
≥10 759 1.46 0.90 3.2
10-15 622 1.47 0.93 3.2
≥16 137 1.45 0.76 3.2
Tanner stage
I 384 0.93 0.72 2.6
≥II 643 1.51 0.89 3.2
II-IV 518 1.54 0.93 3.3
V 125 1.37 0.66 2.7
Bold data: HOMA-IR threshold for insulin resistance defined by the method of
95th percentile of reference population (with or without stratification of
pubertal status).
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number of MS components and the risk of MS increased
with rising HOMA-IR percentiles. As the number of MS
related components increased, mean BMI, WC, SBP, DBP,
FAT%, TG showed a gradually significant increase. Simi-
larly, the mean insulin and HOMA-IR values increased
with the number of MS components. From another point
of view, we show the ORs of suffering MS according to IR
categories. We use the group with HOMA-IR valuesFigure 1 ROC curve analyses of HOMA-IR cutoff in different Tanner st
prepubertal subjects. Center: ROC curve analyses in pubertal subjects. Righbelow the 20th percentile as a reference, and we find that
the odds of developing MS (adjusted for gender, age and
tanner stage) increase as a function of IR. Participants in
the highest quintile of HOMA-IR were about 60 times
more likely to be classified with metabolic syndrome than
those in the lowest quintile. Although the data are cross-
sectional, it is not possible to identify the direction of
causality among metabolic syndrome and HOMA-IR,and
the relationship between insulin resistance and metabolic
syndrome might be different in other samples. Neverthe-
less, the key implications are that youths with high insulin
and HOMA-IR levels have a much greater risk of being
classified with metabolic syndrome. Therefore, evaluation
of insulin resistance as a pathological or physiological
disease as well as early intervention will help control and
reduce the currency of relevant diseases.
The correlation between HOMA-IR and M-clamp had
been validated in diverse adult populations. Furthermore,
two studies have described the pediatric information on its
validation about clamps [8,9]. Although it is more difficult
to define HOMA-IR cut-off points for diagnosis of insulin
resistance in youths than that in adults due to lack of
longitudinal evidence in youths for risk prediction of car-
diovascular outcomes, there were a few studies on
HOMA-IR utility in pediatric populations [28,29] and
some methods for defining cutoff values of HOMA-IR. In
most studies, cut-off points for diagnosis of insulin resist-
ance have been defined based on HOMA-IR distribution
in reference population. Values based on the 95th percent-
ile [30-32], lower boundary of the top quintile [33,34]
ortertile [35] of HOMA-IR obtained from population stud-
ies or non-obese subjects with no metabolic disorders have
been used previously. In other studies, presence ofage children and adolescents. Left: ROC curve analyses in
t: ROC curve analyses in total participants.
Table 4 Prevalence of insulin resistance (%) according to various HOMA-IR cutoffs in cardio metabolic risk factors
Total(N = 3203) Prepuberty(N = 1084) Puberty(N = 2119)
Cardiometabolic
risk actors
2.3 3.0 1.7 2.6 2.6 3.2
(ROC) (>95th percentile in normal
subjects)
(ROC) (>95th percentile in normal
subjects)
(ROC) (>95th percentile in normal
subjects)
MS(ATP III) 79.0 61.6 86.0 53.3 77.3 63.5
WC≥ 90th percentile 65.0 45.7 67.2 36.0 67.9 51.8
HDL-C≤ 5th
percentile
61.9 44.0 62.9 32.3 58.3 42.6
TG≥ 90th percentile 59.9 42.5 67.7 38.9 55.1 42.2
FBG≥ 5.6 mmol/L 65.2 47.7 62.0 34.0 64.5 51.6
BP ≥ 95th percentile 57.9 41.8 64.9 34.6 56.5 43.5
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sidered for defining cut-off values of HOMA-IR by using
ROC statistical method. Youden index and the distance
from the top left corner of the ROC curve are two
methods commonly used in previous work to determine
the best HOMA-IR cut-off [33,36-38]. In our study, the
present HOMA-IR cutoff point corresponding to the 95th
percentile of our healthy reference children was 3.0 for
whole referent and 2.6 for children in prepubertal stage
and 3.2 in pubertal period, respectively. The optimal point
for diagnosis of MS was 2.3 in total referent, 1.7 in pre-
pubertal stage and 2.6 in pubertal period in ROC curve
analysis.
Although HOMA-IR is wildly used in population-based
studies, many factors involved in the inconsistencies of
HOMA-IR should be stressed. Firstly, it is expected to be
different in prepubertal and pubertal children as we show
in this study. A transient insulin resistance develops in chil-
dren during puberty. This insulin resistance emerging dur-
ing pubertal maturation is accepted as a physiological
condition rather than pathologic [39,40]. Some cross-
sectional studies have shown that insulin resistance
increases with the onset of puberty, makes a peak at Tanner
stage 3 and recedes to prepubertal levels at the end ofFigure 2 Prevalence of insulin resistance according to various
HOMA-IR cutoffs in different weight status.puberty [41-43]. Longitudinal studies have found a 30% de-
crease in insulin sensitivity between Tanner stages I and V
[44]. However, this decrease was found to return to normal
at the end of puberty [45]. In our study, while no difference
for gender was detected in HOMA-IR cut-off values, it was
higher in the pubertal period than that in the prepubertal
period. A similar result was found in the different age
phases; the HOMA-IR threshold is rapidly increased when
children reach the age of 10 years, when most commence
puberty. Therefore, it is important that, in the evaluation of
insulin resistance in children and adolescents, different
threshold values should be used according to puberty stage
or age. Secondly, Different cut-off points might be selected
to optimize sensitivity versus specificity depending on the
study purpose. We defined a HOMA cutoff point for diag-
nosis of MS of 1.7 in prepubertal stage yielding a sensitivity
of 86% and a specificity of 67% in the ROC curve. In puber-
tal population, the HOMA cutoff point of 2.6 produced a
sensitivity of 78% and a specificity of 67%. A screening test
requires high sensitivity and moderate specificity, whereas a
diagnostic test requires a much higher specificity. In our
study, the 95th percentile of HOMA-IR for normalsubjects
in prepubertal stage was 2.6 and the sensitivity and the spe-
cificity of this point in the ROC analysis are were 54% and
85% respectively. The 95th percentile of HOMA-IR for pu-
bertal adolescents of 3.2 leaded to a sensitivity of 64% and a
specificity of 80%. Due to the fact that our sample size was
large, we are able to propose precise cut-off limits based on
the results of this study. This may be useful for different
purposes, such as early intervention or early diagnose of in-
sulin resistance in clinic. Thirdly, HOMA-IR is a function
of both insulin and glucose, and glucose is included in the
unified criteria of MS. However, insulin assays have not yet
to be standardized and assessment methods differ between
laboratories [46,47]. This makes comparison with different
studies difficult.
Conclusions
Our study determined HOMA-IR cut-off values of dif-
ferent pubertal status regarding the diagnosis of MS
Yin et al. Diabetology & Metabolic Syndrome 2013, 5:71 Page 8 of 9
http://www.dmsjournal.com/content/5/1/71based on a large cohort of Chinese schoolchildren. Our
results showed the prevalence of insulin resistance based
on different thresholds stratified by weight status and
cardio metabolic risk factors. The high prevalence of
insulin resistance in obesity among Chinese children and
teenagers, predicts an increasing burden of metabolic
disease in the near future. HOMA-IR may be useful for
early evaluating insulin resistance in children and teen-
agers and could have a long-term benefit of preventive
and diagnostic therapeutic intervention [48].
Limitations
Several limitations of our study should be acknowledged.
Firstly, the results were limited by the use of HOMA rather
than the gold standard technique, that is, hyperinsulin-
emiceuglycemic clamp, for its complexity in large pediatric
population. Secondly, there are numerous criticisms about
the use of HOMA-IR, and the most important issue is the
lack of standardization of insulin measurements, which
makes comparison with other studies or population diffi-
cult. Thirdly, in our study, participants were children and
adolescents predominately from Beijing, China. It is not
possible to generalize the HOMA-IR cutoff to other ethnic
populations.
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